AstraZeneca and the European Union have reached an agreement to end lawsuits against former supplies of their COVID vaccine. The drugmaker said its agreement with the European Commission, the executive arm of the European Union, “ends legal proceedings on the execution of an advance purchase agreement for the delivery of the COVID-19 vaccine Vaxazevaria.”
The commission had initiated legal action against them. astraZeneca In Brussels on 21 April 2021 for the withdrawal of its contract for the supply of a COVID-19 vaccine and for lack of a credible plan to ensure timely delivery. Court hearings were scheduled for the end of September 2021.
The agreement will pave the way for AstraZeneca to resume delivery of its vaccine doses to European countries, which have been hit by lawsuits and concerns over side effects. It will also help the EU accelerate vaccination.
Under the latest agreement, AstraZeneca has committed to deliver 60 million doses of the vaccine by the end of this quarter, 75 million by the end of the fourth quarter of 2021 and 65 million by the end of the first quarter of 2022.
Member States will be provided with regular delivery schedules, and capped exemptions will apply in the event of any delayed doses.
AstraZeneca said it, along with its partners, has supplied more than 1.1 billion doses of the vaccine to more than 170 countries, about two-thirds of which have gone through the COVAX facility to low- and lower-middle-income countries.
vaxazevaria, or ChAdOx1-S [Recombinant], developed jointly by AstraZeneca and the University of Oxford. It is manufactured and supplied in India by: Cowishield Located in Pune. By Serum Institute of India (SII).
The AstraZeneca-Oxford COVID-19 vaccine uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infection in chimpanzees and contains the SARS-CoV-2 virus spike protein. contains genetic material. After vaccination, surface spike proteins are produced, which subsequently provoke the immune system to attack the SARS-CoV-2 virus when it infects the body.
The incidence of blood clots has been reported in a small group of people after being vaccinated.
“Early diagnosis allows appropriate treatment of these events and there is no increased risk of TTS” [thrombocytopenia] at the second dose, compared to rates expected in the general population,” AstraZeneca said.
“We are fully committed to manufacturing Vaxazevaria for Europe after continuing to supply over 140 million doses to date to no avail. We also look forward to working with the European Commission in a joint effort to further support COVAX,” said Ruud Dober, Executive Vice President, Biopharmaceuticals Business Unit, AstraZeneca.
Don’t miss a story! Stay connected and informed with Mint.
download
Our App Now!!
.